CG Oncology announces offering of 8M shares of common stock

CG Oncology (CGON) announced that it has filed a registration statement on Form S-1 with the U.S. SEC relating to a proposed underwritten public offering of 7.3M shares of its common stock. Additionally, an existing stockholder of CG Oncology intends to offer and sell 700,000 shares of CG Oncology’s common stock in the proposed offering. CG Oncology will not receive proceeds from the sale of the shares by the selling stockholder. Morgan Stanley & Co., Goldman Sachs & Co., TD Cowen and Stifel, Nicolaus & Company, are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager for the offering.